Introduction

Prostate cancer (PC) is the most common malignant tumor in men and the second most common cause of cancer-associated mortality (1). In patients treated for metastatic PC the progression from a castration-sensitive to a castration-resistant stage marks the transition to the lethal phenotype of the disease [metastatic castration-resistant PC (mCRPC)]. In recent years, several new agents have been approved for treatment of mCRPC. They include androgen receptor-targeted therapies with abiraterone and enzalutamide as well as taxane-based chemotherapy.
with docetaxel or cabazitaxel or the bone-targeting agent radium-223-dichloride. Despite these innovations for mCRPC therapy more than 250,000 men still die of PC worldwide each year and its treatment remains challenging. Therefore, the development of novel therapeutic regimens exhibiting both effective antitumor activity and a tolerable side effect profile is warranted.

**Tumor therapy using prostate-specific membrane antigen (PSMA)-targeted radionuclides**

PSMA is a transmembrane protein over-expressed in PC cells in comparison to benign prostatic tissue (2). Most importantly, PSMA expression progressively increases in higher grade cancers, metastatic disease and castration-resistant PC (2,3). PSMA has a catalytic site located in its extracellular domain resulting in its internalization after ligand binding (3).

At present, two PSMA ligands are reported to be most frequently used for radio-ligand therapy (RLT): PSMA-617 and PSMA-I&T (imaging and therapy), both labelled to the low-energetic beta-emitter Lutetium-177 (4,5). Lu-177-PSMA-617 was first characterized by the Heidelberg group after initial experience with I-131-MIP 1095 (6,7). Lu-177-PSMA-I&T (imaging and therapy) was first reported at the Technical University of Munich and also demonstrated nanomolar affinity for PSMA (8). To date, biodistribution of both ligands seem to have similar properties, albeit a head-to-head comparison has not yet been performed. For ease of reading, both ligands are henceforth summarized as Lu177-PSMA.

Organs at risk for a critical radiation dose upon treatment with Lu177-PSMA include the salivary glands and the kidneys (9). Review of available literature suggests that the radiation dose to bone marrow, spleen and liver are below critical limits (10).

As an alternative a PSMA-ligand labeled to the high-energetic alpha-emitter Actinium-225 (Ac-225) may be offered to patients presenting with progressive mCRPC. To date, available date suggests that RLT using Ac-225-PSMA-617 may still be active in patients progressing under Lu177-PSMA. However, treatment-related permanent xerostomia remains a relevant side effect, frequently leading to discontinuation of treatment (11,12). We present the following article in accordance with the NARRATIVE REVIEW reporting checklist (available at http://dx.doi.org/10.21037/apm-20-1135).

**Methods**

This narrative review comprehensively summarizes the current knowledge on efficacy and safety of both Lu177-PSMA but also Ac225-PSMA RLT for routine clinical practice. Suitable, accepted literature on Lu177- and Ac225 PSMA in PC, published and retrievable on PubMed and GoogleScholar from 2014 until August 30, 2020 was reviewed. Moreover, abstract data published at the ASCO2020 was reviewed and, if applicable, included in the review. An outlook on ongoing and future trials is given at the end of the discussion.

**Protocol for Lu177-PSMA RLT**

To date, Lu177-PSMA RLT is offered to mCRPC patients within a compassionate use program as a salvage therapy after having exhausted conventional therapies or within clinical trials owing to the fact that this treatment regimen has not been approved, yet (13-16). The following course of treatment is currently used in daily routine:

(I) Confirmed, sufficient PSMA expression of detected metastases proven by PSMA-directed positron-emission tomography/computed tomography (PET/CT). Based on the study by Hofman et al. the minimum SUVmax of metastases ought to be at least 1.5 times the SUVmean of the liver to ensure sufficient PSMA expression in potential Lu177-PSMA RLT patients (13). The EANM guidelines recommend at baseline an additional FDG-PET/CT to exclude patients with FDG-positive, but PSMA-negative PC metastases (15,17).

(II) RLT using Lu177-PSMA is offered at nuclear medicine centers. Following slow intravenous application of the radionuclide (slow injection over 10–15 min) a post-therapeutic scintigraphy is performed on days 1 or 2 after treatment to evaluate in-vivo distribution of the radionuclide. Patients are usually admitted to the hospital for 2–4 days under radiation-controlled conditions. The target radiation activity for Lu177-PSMA is 4–8 giga-becquerel and is determined on individual basis.

(III) Assuming treatment response, patients typically receive Lu177-PSMA every 6 weeks for up to 4–8 cycles.

(IV) Restaging is most frequently performed after every second cycle of treatment as proposed by the EANM guidelines (15). While some institutions
perform restaging using conventional imaging with CT and bone scan, others use molecular imaging with PSMA/CT. It has to be noted that tumor progression on imaging using PSMA-PET/CT may be detected earlier than with conventional imaging leading to shorter treatment with PSMA-RLT.

Anti-tumor effect of Lu177-PSMA RLT

The first studies investigating the activity of Lu177-PSMA RLT were retrospective and characterized by small sample sizes in mCRPC patients who exhausted conventional systemic treatments, thus representing collectives at advanced stages of the disease. Overall, the majority of these first, but also later studies reported promising results with ≥50% PSA declines observed in at least one third of patients. Table 1 illustrates an overview of selected retrospective and prospective studies available to date.

In a large German multicenter retrospective analysis involving 148 patients treated with Lu177-PSMA-617, a ≥50% PSA decline was defined as biochemical treatment response and was observed in 45% of patients (1). Likewise, a meta-analysis of 17 studies involving a total of 681 mCRPC patients undergoing Lu177-PSMA RLT reported a ≥50% PSA decline in roughly 45% of the patients (27). Similarly, data collected at our center at the Technical University Munich showed a ≥50% reduction of PSA serum levels in 38 of 100 analyzed patients under Lu177-PSMA-I&T following a median of 3 approved treatment regimens, underlining the promising activity of Lu177-PSMA in late-stage mCRPC (4,5). A subsequent subgroup analysis by clinically relevant factors revealed a significantly worse biochemical response in patients with visceral metastases. Moreover, considering progression-free survival (PFS) and overall survival (OS), both visceral metastases as well as increased serum lactate dehydrogenase (LDH) concentrations were significant independent predictors of worse treatment outcome (5). In patients with visceral metastasis median OS was significantly lower as compared to patients without evidence for visceral metastasis (7.6 versus 14.0 months, respectively). Similarly, PFS was significantly shorter for patients with visceral metastasis as compared to patients without (3.9 versus 5.9 months, respectively). Moreover, patients whose PSA concentrations achieved a decline ≥50% within the first 12 weeks under Lu177-PSMA RLT had a significantly improved median PFS (8.1 versus 0.4 months) (5).

The majority of available studies on Lu177-PSMA RLT investigated its activity in cohorts of mCRPC patients beyond the second or third line of conventional treatment. To further investigate the role of pretreatment with chemotherapy in mCRPC patients undergoing Lu177-PSMA RLT, Bayer et al. retrospectively analyzed 167 patients who underwent PSMA-RLT and stratified the cohort by taxane-pretreatment status (24). Of note, taxane-naive patients receiving Lu177-PSMA RLT had a significantly longer median radiographic PFS than taxane-pretreated patients (8.8 versus 6.0 months), suggesting that patients may benefit from providing Lu177-PSMA RLT to mCRPC patients at an earlier time during the course of disease (24). Similarly, taxane-naive patients had a longer OS as compared to taxane-pretreated patients (27.1 versus 10.7 months, respectively).

A systematic review by von Eyben et al. investigated the activity of Lu177-PSMA RLT in comparison to conventional third line systemic treatments (abiraterone, enzalutamide or cabazitaxel). The results of this study showed a significantly better biochemical response in patients treated with Lu177-PSMA RLT as compared to other third line options. Overall, 43% of the patients treated with Lu177-PSMA RLT showed a ≥50% PSA decline, whereas only 21% of patients receiving conventional third line treatments achieved a PSA decline ≥50% (28). These results may further support a future earlier treatment algorithm role of Lu177-PSMA RLT not only as last or third line option.

In 2018, the first prospective single-arm Phase II study confirmed the activity of Lu177-PSMA RLT in 30 mCRPC patients pretreated with at least one taxane-based chemotherapy and/or androgen receptor target therapies (abiraterone, enzalutamide). The findings of this study revealed a ≥50% PSA decline in 57% of the patients as well as a significant improvement in their quality of life (13). More recently, in November 2019, Violet et al. published the long-term outcomes of this same cohort including a 20-patient extension. The authors reported a median OS of 13.3 months with a statistically significant longer OS of 18.4 months in patients who had a PSA decline ≥50% (22). Novel data presented at the ASCO 2020 of a post-hoc analysis including 43 patients with progressive mCRPC in the RESIST phase II trial confirmed a significantly improved longer PFS (13.4 versus 3.3 months) and OS (20.1 versus 11.6 months) in patients who had a PSA decline ≥50% (29).

At ASCO 2020 the Hofman group presented preliminary
Table 1 Overview of publications on case-series investigating the effect of PSMA RLT (the overview makes no claim to completeness)

<table>
<thead>
<tr>
<th>RLT</th>
<th>Author</th>
<th>Pts, n</th>
<th>Lines of treatment</th>
<th>CTX-naive pts, n (%)</th>
<th>OS</th>
<th>PFS</th>
<th>PSA-decline &gt;50%, n (%)</th>
<th>Toxicity, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{131}$I-MIP-1095</td>
<td>Zechmann et al. (18)$^\dagger$</td>
<td>28</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>17/28 (61%) (BR)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>$^{177}$Lu-PSMA-617</td>
<td>Kratochwil et al. (7)$^\dagger$</td>
<td>1</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>1/1 (100%) (BR)</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kratochwil et al. (19)</td>
<td>30</td>
<td>&gt;1</td>
<td>16 (53%)</td>
<td>N/A</td>
<td>13/30 (43%) (W8)</td>
<td>Anemia, 1 (3%) TP, 1 (3%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ahmadzadehfar et al. (20)</td>
<td>24</td>
<td>&gt;1</td>
<td>14 (58%)</td>
<td>N/A</td>
<td>13/22 (60%) (BR)</td>
<td>Anemia, 2 (8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rahbar et al. (21)$^\dagger$</td>
<td>82</td>
<td>&gt;2</td>
<td>30 (37%)</td>
<td>N/A</td>
<td>23/74 (31%) (BR)</td>
<td>Anemia, 1 (1%) TP, 1 (1%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hofman et al. (13)</td>
<td>30</td>
<td>&gt;2</td>
<td>4 (13%)</td>
<td>13.5</td>
<td>7.6</td>
<td>17/30 (57%) (BR)</td>
<td>Anemia, 4 (13%) TP, 3 (10%)</td>
</tr>
<tr>
<td></td>
<td>Violet et al. (22)</td>
<td>50</td>
<td>&gt;2</td>
<td>8 (16%)</td>
<td>13.3</td>
<td>6.9</td>
<td>32/50 (64%) (BR)</td>
<td>Anemia, 5 (10%) TP 4 (8%)</td>
</tr>
<tr>
<td></td>
<td>Hofman et al. (17)</td>
<td>98</td>
<td>&gt;1</td>
<td>0</td>
<td>N/A</td>
<td>64/98 (66%) (BR)</td>
<td>Neutropenia 4 (4%), TP 11 (11%)</td>
<td></td>
</tr>
<tr>
<td>$^{177}$Lu-PSMA-I&amp;T</td>
<td>Weineisen et al. (8)$^\dagger$</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>1/1 (100%) (BR)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Baum et al. (23)</td>
<td>56</td>
<td>&gt;3</td>
<td>31 (55%)</td>
<td>28</td>
<td>13.7</td>
<td>33/56 (59%) (BR)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Heck et al. (4)</td>
<td>22</td>
<td>&gt;2</td>
<td>0 (0%)</td>
<td>N/A</td>
<td>10/18 (56%) (BR)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heck et al. (5)</td>
<td>100</td>
<td>&gt;2</td>
<td>16 (16%)</td>
<td>12.9</td>
<td>4.1</td>
<td>38/100 (38%) (BR)</td>
<td>Anemia, 9 (9%) neutropenia, 6 (6%), TP, 4 (4%)</td>
</tr>
<tr>
<td>$^{177}$Lu-PSMA-I&amp;T/617</td>
<td>Barber et al. (24)</td>
<td>167</td>
<td>1–2</td>
<td>84 (50%)</td>
<td>&gt;10.7</td>
<td>&gt;6</td>
<td>65/132 (49%) (AR)</td>
<td>Anemia 8 (4%), leucopenia 2 (2%), TP 4 (2%)</td>
</tr>
<tr>
<td>$^{225}$Ac-PSMA-617</td>
<td>Kratochwil et al. (25)$^\dagger$</td>
<td>2</td>
<td>&gt;4</td>
<td>0 (0%)</td>
<td>N/A</td>
<td>2/2 (100%) (BR)</td>
<td>Xerostomia 1 (50%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kratochwil et al. (12)</td>
<td>40</td>
<td>&gt;3</td>
<td>12 (30%)</td>
<td>&gt;12</td>
<td>6</td>
<td>24/38 (63%) (BR)</td>
<td>Xerostomia, 4 (10%)</td>
</tr>
<tr>
<td></td>
<td>Sathekge et al. (26)</td>
<td>73</td>
<td>1–2</td>
<td>36 (49%)</td>
<td>18</td>
<td>15.2</td>
<td>51/73 (70%)</td>
<td>Anemia 5 (7%), leucopenia 2 (3%), renal failure 2 (3%), renal failure 3 (4%)</td>
</tr>
</tbody>
</table>

AR, any response; BR, best response. CTX, chemotherapy; CX, cycles. N/A, not available. Pts, patients. TP, thrombopenia. W8, after 8 weeks. $^\dagger$, original publication/first description of respective RLT; $^\ddagger$, publication includes patients reported in Ahmadzadehfar et al., Oncotarget 2016; $^\S$, publication includes patients reported in Hofman et al., Lancet Oncol 2018.
results of a first randomized Phase-2-trial (TheraP), which evaluates Lu177-PSMA versus cabazitaxel in 200 men with mCRPC upon progression to docetaxel (17). The reported trial results showed an improved biochemical response rate of Lu177-PSMA as compared to cabazitaxel in patients progressing after docetaxel (PSA decline ≥50% achieved in 66% versus 37%). At a median follow-up of 13 months, treatment with Lu177-PSMA significantly improved biochemical PFS as compared to cabazitaxel (HR 0.69, 95% CI: 0.5–0.95) (17). Data on stronger secondary endpoints like PFS and OS data are still pending. It has to be noted that the biochemical response rate in the Lu177-PSMA arm was higher compared to data from retrospective trials. One explanation might be the patient selection. In addition to a PSMA-PET/CT confirming PSMA-expression in PC metastases, an FDG-PET/CT was performed at baseline to exclude FDG-positive/PSMA-negative PC metastases. With this additional imaging procedure 28% of mCRPC patients were excluded from the trial due to PSMA-negative PC metastases.

An ongoing focus of current research is focusing on improving response rates. Preliminary, promising results of a prospective phase-I/II dose escalation trial were presented at the ASCO 2020. The data showed that fractionated dosing up to 22.2 GBq in a population unselected for PSMA expression in a single cycle was safe in this cohort of 44 mCRPC patients with a >50% PSA decline observed in 66.7% of patients and a median OS of 16 months (30). Also, the use of radiosensitizers to increase response rates is currently being investigated. Emmett et al presented updated interim data of the LuPIN trial to investigate the safety and efficacy of a combination of Lu177-PSMA with idronoxil (NOX66) at ASCO 2020. The PSA responses >50% in 62% of 32 mCRPC patients and a median survival of 17.1 months are encouraging and warrant further trials to investigate the role of both fractionated dosing and the use of radiosensitizers to increase treatment responses (31).

**Re-challenge using Lu177-PSMA RLT**

Of interest, the abovementioned study by Violet et al. also investigated the effect of additional cycles of Lu177-PSMA in comparison to other systemic treatments at relapse to Lu177-PSMA RLT as a secondary endpoint (22). In this study, patients who had shown an initial response to Lu177-PSMA RLT as defined by a PSA decline ≥50% and subsequently progressed in the treatment-free interval after PSMA-RLT were considered for additional Lu177-PSMA cycles (“Re-challenge”). In this re-challenge setting 11 of 15 patients (73%) still had a PSA decline ≥50% with a median OS of 26.6 months. However, although a considerable number of patients responded to re-challenge, the response to Lu177-PSMA RLT in a re-challenge setting seemed less durable with a trend for a shorter PFS as compared to the PFS observed upon initial Lu177-PSMA RLT (no direct, statistical comparison was reported). Data collected at our center at the Technical University Munich showed a PSA decline ≥50% in 3 of 8 patients (37.5%) who had Lu177-PSMA RLT re-challenge with a median biochemical PFS and OS of 3.2 and 14.0 months, respectively (32).

These findings suggest that a re-challenge with Lu177-PSMA might be a valuable treatment option in patients who had an excellent prior response to Lu177-PSMA and subsequently progressed following a treatment pause.

**Safety of Lu177-PSMA RLT**

Treatment with Lu177-PSMA is generally well-tolerated. However, primary safety concerns are the physiologic expression of PSMA in salivary glands, kidneys and treatment-associated myelosuppression.

Low degree Xerostomia due to radiation toxicity are typically transient, occur within the first 1–2 weeks following infusion of Lu177 PSMA and are seen in roughly 15–24% of the patients (5,27,33). Other common, non-hematological side-effects may be fatigue and nausea, seen in roughly 25% and 10%, respectively. The incidence of treatment-associated nephrotoxicity is low (9.5%) and usually rather mild (27). Severe grade 3–4 hematologic toxicity was observed in less than 10% in our retrospective study cohort (5). Similarly, the prospective phase II trial by Hofman et al. reported a relatively low frequency of grade 3–4 thrombocytopenia and anemia (17% and 23%, respectively) (13). Notably, it appears that treatment associated hematological toxicity primarily occurs in patients with baseline anemia/thrombocytopenia due to reduced bone marrow reserve following previous chemotherapy or metastatic osseous infiltration (13). Systematic reviews by von Eyben et al. and Emmett et al. underlined these observations and reported mild grade 1-2 anemia or thrombocytopenia in 10–25% of patients with metastatic bone marrow infiltration at baseline whereas no hematologic toxicity was observed in patients without baseline bone marrow damage (28,33).
RLT with Actinium-255-PSMA-617

Despite its favorable toxicity and promising activity in previously published studies, roughly one fourth of patients have shown resistance to Lu177-PSMA RLT despite confirmed sufficient PSMA expression (27). An alternative or salvage treatment approach upon progression under Lu177-PSMA is RLT with Actinium-255 PSMA-617 (AcPSMA). Contrary to the beta particle emitter Lu177, treatment with Ac-255 takes advantage of the shorter tissue penetration range, higher linear energy transfer and favorable microdosimetry provided by the alpha particles. The use of the alpha-emitter Ac255 labelled to PSMA-617 was first described by Kratochwil et al. in 2016 (25). In this study, two patients were treated with Actinium-255 PSMA-617 RLT (activity 100 kBq/kilogram bodyweight, applied at 8-week intervals) showing promising results. Both patients had been extensively pretreated with at least 4 to 5 different mCRPC treatment regimens. One patient had shown progression upon treatment with Lu177 PSMA. Both patients showed a biochemical and radiographic complete remission following three cycles of Actinium-255 PSMA-617. Although there was no severe hematologic toxicity observed, xerostomia occurred in both patients (25). One patient had severe xerostomia requiring permanent saliva substitution via spray. A more recent, larger retrospective publication by Kratochwil et al. [2018] reported the application of up to three cycles of Actinium-255 PSMA-617 at 8-week intervals in 40 mCRPC patients in late stage mCRPC who had exhausted conventional therapies including 7 patients who had prior treatment with Lu177-PSMA (12). A total of 63% patients had a PSA decline >50% with a median OS of >12 months and a median PFS of 7 months. Data collected at our institution at the Technical University Munich of 26 patients undergoing Ac255 PSMA for late stage mCRPC who had shown progression upon Lu177-PSMA treatment and had previously received at least second line antihormonal treatment and taxane based chemotherapy. Our data revealed a PSA decline >50% in 65% of patients with a PSA PFS of 5 months and an OS of 7.7 months for salvage-treatment with Ac255-PSMA after progression under Lu177-PSMA. Of interest, Sathekge et al. investigated the use of Ac255-PSMA in 17 mCRPC chemotherapy-naïve patients and reported a PSA decline >90% in 14/17 patients, suggesting that Ac255-PSMA may be even more active at earlier disease stages (34).

However, to date, contrary to Lu177-PSMA, a prospective, randomized trial on Ac255-PSMA is not available. Reported retrospective data indicates that treatment with Actinium-255 PSMA-617 offers promising rates of tumor control. However, alpha emitter based RLT using Ac255-PSMA is associated with increased rates of xerostomia which may lead to discontinuation of treatment. Data from our workgroup showed that grade I-II xerostomia led to 6 patients (33%) asking to discontinue treatment, whereas in the larger subset analyzed by Kratochwil et al. 10% of patients discontinued treatment due to intolerable xerostomia (11,12). Strategies to overcome this limitation are eagerly needed. These may include reduction of treatment activity and tandem therapy using both Ac-225-PSMA and Lu-177-PSMA simultaneously with lower activities of both radionuclides (35).

Outlook on PSMA RLT

Currently recruiting studies compare the safety, tolerability and efficacy of the combination of PSMA lutetium with the immune-checkpoint inhibitor pembrolizumab (e.g., phase I: NCT03658447, NCT03805394) or olaparib (e.g., phase I, NCT03874884) or as stand-alone treatment (e.g., phase II, NCT03454750, NCT04188587). The UpFrontPSMA phase II trial (NCT04343885) compares the safety and benefit of two inductive cycles of Lu-177-PSMA followed by six cycles of docetaxel versus six cycles of docetaxel alone patients with newly diagnosed high volume metastatic castration-sensitive PC. A non-randomized phase I/II trial (LuTectomy) investigates the dosimetry, efficacy and toxicity of two neoadjuvant cycles of Lu-177-PSMA in men with high-risk localized or locoregional advanced PC followed by radical prostatectomy (NCT04430192). The recently initiated open label, randomized, stratified, two-arm, multicenter phase II (ENZA-p) trial compares activity and safety of Lu-177-PSMA in combination with enzalutamide to enzalutamide alone in chemotherapy naïve mCRPC patients (NCT04419402). One prospective phase III trial (VISION study) is currently recruiting (NCT03511664).

Preliminary data of the randomized phase II (TheraP) trial presented at the ASCO2020 showed an improved biochemical response rate of Lu177-PSMA as compared to cabazitaxel in patients progressing upon docetaxel. The results of the prospective phase III VISION study investigating the efficacy of Lu177-PSMA in combination with standard of care versus best standard of care alone are eagerly anticipated.

The results of these, but also further prospective trials will help identify to role of Lu177-PSMA in comparison...
with approved treatment regimens and its application at an earlier time point in the treatment sequence of mCRPC. Moreover, additional trials are awaited to investigate the role of Lu-177-PSMA in combination with other drugs and its application in castration-sensitive PC, e.g., combination with standard of care for metastatic hormone-sensitive disease in the UpFrontPSMA trial and application in high-risk localized/locally advanced PC in the LuTectomy trial.

Summary

Available data suggests that RLT with Lu177-PSMA is an active therapy in late stage mCRPC and mostly well tolerated with a low side effect profile (xerostomia, fatigue or nausea). Severe, hematological side effects are rare. Data on treatment with Ac255-PSMA indicate a promising effect on tumor control in both early and late stage mCRPC. However, concerns are raised due to treatment-associated and mostly permanent xerostomia, which seems to frequently lead to treatment discontinuation in a relevant number of patients.

Currently available, prospective phase II data on Lu177-PSMA confirm previously published retrospective data. The results of ongoing phase II and phase III trials are eagerly anticipated to assess the efficacy of Lu177-PSMA in comparison with approved treatment regimens.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at http://dx.doi.org/10.21037/apm-20-1135

Peer Review File: Available at http://dx.doi.org/10.21037/apm-20-1135

Provenance and Peer Review: This article was commissioned by the Guest Editor (Tilman Todenhöfer) for the series “Management of Advanced Genitourinary Malignancies” published in Translational Andrology and Urology. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apm-20-1135). The series “Management of Advanced Genitourinary Malignancies” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


14. Deutsche Krebsgesellschaft, Deutsche Krebshilfe A. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Available online: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_0/LL_Prostatakazinom_Langversion_5.1.pdf


28. von Eyben FE, Roviello G, Kiljunen T, et al. Third-


